Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR. (3rd July 2019)

• Record Type: Journal Article
• Authors: Fietz, Thomas; Lück, Andreas; Schulz, Holger; Harde, Johanna; Losem, Christoph; Grebhardt, Sina; Wolff, Thomas; Potthoff, Karin; Müller, Udo; Zaiss, Matthias; Kurbacher, Christian Martin
• Is Part Of: Current medical research and opinion. Volume 35:Number 7(2019)
• Page Start: 1127
• Page End: 1138
• Publication Date: 2019-07-03
• Subjects: Lipegfilgrastim -- granulocyte-colony stimulating factor -- chemotherapy-induced febrile neutropenia -- prophylaxis -- routine clinical practice; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2018.1560200
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objectives: The non-interventional study (NIS) NADIR (DRKS00005711) evaluated the effectiveness and safety of prophylaxis with lipegfilgrastim, a glycopegylated granulocyte-colony stimulating factor, in 2500 patients undergoing chemotherapy in routine clinical practice. Primary objective was the incidence of chemotherapy-induced severe neutropenia, febrile neutropenia (FN), and neutropenia-associated complications. Methods: NADIR was a prospective NIS conducted in 201 study centers in Germany. Results: The analysis included 2489 patients. Main tumor types were breast cancer ( n = 1198, 48.1%), lung cancer ( n = 303, 12.2%), non-Hodgkin lymphoma (NHL; n = 337, 13.5%), and prostate cancer ( n = 111, 4.5%). Nine hundred and ten (36.6%) patients were aged ≥65 years (regarded as "elderly" patients). Severe neutropenia (CTCAE grade 3/4) was reported in 26.8% ( n = 666) and 25.2% ( n = 229) of the total population and elderly patients, respectively. FN was documented in 2.7% ( n = 68) of the total population vs 3.0% ( n = 27) of elderly patients. Primary prophylaxis with lipegfilgrastim among patients with high risk of FN (>20%) was documented in 83.5% of the total population and 75.1% of elderly patients. Infections (CTCAE grade 3/4) were documented in 99 patients (4.0%) in the total population vs 47 (5.1%) elderly patients. Fatal infections were reported in 14 (0.6%) patients in the total population vs 11 (1.2%) elderly patients. Overall, most frequent lipegfilgrastim-related adverse events (AEs) included bone pain (8.0%), anemia (3.2%), leucocytosis (2.7%), and thrombocytopenia (2.5%). Of the patients, 18.0% had ≥1 documented serious AE; none of the fatal events (2.7%) was lipegfilgrastim-related. Conclusions: Lipegfilgrastim administered to patients with solid tumor/NHL undergoing chemotherapy in routine clinical practice showed similar effectiveness and safety compared to the pivotal trials. Trial registration: German Clinical Trials Register identifier: DRKS00005711.